ArticleRespiration; international review of thoracic diseases2026
Nontuberculous Mycobacteria in Primary Ciliary Dyskinesia: A National Multicenter Cohort Study.
Article in Respiration; international review of thoracic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe prevalence and clinical significance of nontuberculous mycobacteria (NTM) in individuals with primary ciliary dyskinesia (PCD) remain unclear, with most data extrapolated from cystic fibrosis. This first national multicenter cohort study evaluating NTM in PCD patients aimed to determine the prevalence, species distribution, and clinical impact of NTM isolation.
methodsA retrospective, longitudinal study was conducted across four tertiary centers in Israel (2010-2024). Patients with confirmed PCD were evaluated for demographic, clinical, microbiological, and longitudinal lung function data. NTM species were classified by growth rate and pathogenicity. Each NTM-positive PCD patient was matched 1:1 to an NTM-negative PCD patient.
resultsOf 231 patients with PCD, 24 (10.4%) had ≥1 positive NTM culture. Most isolates were slow-growing species, predominantly Mycobacterium simiae. Rapid-growing species, mainly Mycobacterium abscessus, were identified in patients with significantly lower forced expiratory volume in 1 s (FEV1) at the time of NTM isolation when compared with those harboring slow-growing species (43.5% vs. 82.3%, p = 0.03). Chronic isolation occurred in 25% of NTM-positive individuals. Longitudinal analysis showed no significant association between NTM status and FEV1 decline. Intravenous antibiotic use was not higher in NTM-positive patients and did not increase following NTM isolation. Only one patient fulfilled the criteria for NTM pulmonary disease.
conclusionNTM isolation is not uncommon in PCD patients and is often intermittent, mostly by slow-growing species. NTM status was not associated with accelerated FEV1 decline, although rapid growers occurred predominantly in patients with poorer baseline lung function. Routine annual NTM surveillance appears reasonable to better determine prevalence and monitor outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.